Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The C3 Nitazoxanide for Mild to Moderate COVID-19 in HIV-infected and HIV-uninfected Adults With Enhanced Risk: a Double-blind, Randomised, Placebo-controlled Trial in a Resource-poor Setting

NCT04523090 is registered in ClinicalTrials.gov with University of Cape Town as lead sponsor.

NCT NCT04523090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04523090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The C3 Nitazoxanide for Mild to Moderate COVID-19 in HIV-infected and HIV-uninfected Adults With Enhanced Risk: a Double-blind, Randomised, Placebo-controlled Trial in a Resource-poor Setting
Lead sponsor
University of Cape Town
Phase
Phase 2/3
Overall status
Terminated
Start date
August 27, 2020
Completion date
August 12, 2022
Enrollment
322 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19